Polaris Capital Management LLC Purchases Shares of 24,500 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Polaris Capital Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 24,500 shares of the company’s stock, valued at approximately $910,000. Polaris Capital Management LLC owned 0.05% of Amphastar Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in AMPH. GAMMA Investing LLC boosted its position in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the period. Asset Management One Co. Ltd. purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth about $78,000. KBC Group NV lifted its holdings in Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after buying an additional 650 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after buying an additional 301 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $32.21 on Tuesday. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of 10.74, a P/E/G ratio of 2.07 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a 50 day simple moving average of $38.14 and a two-hundred day simple moving average of $43.71. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $31.76 and a fifty-two week high of $56.45.

Insider Activity at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the sale, the director now owns 30,471 shares in the company, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the transaction, the executive vice president now owns 118,469 shares in the company, valued at $5,262,392.98. This represents a 5.58 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is owned by insiders.

Analysts Set New Price Targets

AMPH has been the subject of several research analyst reports. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $50.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.